GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...

Tianjin Darentang Jingwanhong Pharmaceutical received an FDA warning letter for concealing manufacturing information, ...

BeiGene has settled a lawsuit with generics manufacturer MSN Pharmaceuticals, resolving all cases associated with the entry ...

Eli Lilly's oral drug muvalaplin showed significant reductions in lipoprotein(a) levels in a Phase 2 trial of 233 high-risk ...

Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the ...

T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...

Bayer will pay Cytokinetics €50M upfront plus potential milestones for heart drug aficamten in Japan. Heather Turner named chair of Avalyn Pharma and CEO of LB Pharmaceuticals. Multiple companies ...

They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...

Efforts by the pharmaceutical industry to expand access to low-and-middle-income countries need to be “vastly accelerated” ...

Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...